MAINZ BIOMED B.V. MYNZ 深 沪
已收盘 08-29 16:00:00 美东时间
1.68
+0.030
+1.82%
华盛通- 最 高1.69
- 今 开1.66
- 成交量 4.32万股
- 最 低 1.62
- 昨 收 1.65
- 总市值 640.90万
- 52周最高 16.04
- 市盈率 静 --
- 换手率 1.13%
- 52周最低 1.30
- 委 比 -84.86%
- 总股本 381.49万
- 历史最高 1200.00
- 量 比 0.63
- 振 幅 4.24%
- 历史最低 1.30
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mainz Biomed's ColoAlert Receives Swissmedic Approval, Paving Way For Swiss Launch Of Non-Invasive Colorectal Cancer Test
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert®, its non-invasive colorectal
08-13 20:18
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
Mainz Biomed's ColoAlert®, a non-invasive colorectal cancer (CRC) screening test, has received regulatory approval from Swissmedic, allowing its distribution in Switzerland. Targeting individuals aged 50-74, a group of around 2.8 million people, ColoAlert® aims to address the low participation rate in CRC screening programs (below 50%) and support national health goals. The approval follows a partnership with a local Swiss laboratory, enabling br...
08-13 12:01
Mainz Biomed Prices $3.0M Follow-On Offering of Over 2.2M Units Including Ordinary Shares and Series A Warrants
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of
08-04 22:24
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
Mainz Biomed announces a $3.0 million follow-on offering of 2,222,222 units at $1.35 per unit, each consisting of one ordinary share or pre-funded warrant and one Series A warrant exercisable at $1.35 per share. The offering, managed by Maxim Group LLC, is set to close on August 5, 2025, pending customary conditions. The securities are registered under SEC's Form F-1 (File No. 333-289095). Investors can obtain the prospectus from Maxim Group.
08-04 14:22
Mainz Biomed files to sell 1.47M ordinary units
Mainz Biomed (NASDAQ:MYNZ) filed a prospectus for the offer and sale of up to 1.47M ordinary units. This preliminary prospectus is not an offer to sell. Filing. More on Mainz Biomed B.V. Mainz Biome...
07-31 04:58
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
Mainz Biomed collaborates with CARE to expand ColoAlert® colorectal cancer screening in Germany, enhancing early detection rates. CARE currently works with 19 health insurance companies, supporting Mainz Biomed's market growth.
07-23 12:01
Mainz Biomed Reviews H1 2025 Accomplishments; Plans To Complete eAArly DETECT 2 Feasibility Study In H2 2025.
Mainz Biomed launched eAArly DETECT 2, a US feasibility study to evaluate the Company's next generation colorectal cancer (CRC) test, integrating its proprietary mRNA biomarkers, AI developed algorithm and FIT test, over
07-15 20:09
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Mainz Biomed has made significant strides in advancing its colorectal and pancreatic cancer screening technologies. The company initiated the eAArly DETECT 2 feasibility study for its next-gen CRC test, launched ColoAlert® in Switzerland, and entered collaborations to expand its product portfolio. Additionally, it secured a license for novel mRNA biomarkers for pancreatic cancer detection, with high sensitivity and specificity, and received publi...
07-15 12:01
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
Mainz Biomed N.V. has received public funding from the German Investitions- und Strukturbank Rheinland-Pfalz (ISB) for its pancreatic cancer project. The state will fund up to 50% of the project’s costs, supporting the company’s non-invasive blood-based screening test for early pancreatic cancer detection. The grant emphasizes the project’s medical and technological relevance, aiming to bridge a critical gap in cancer diagnostics by enabling earl...
06-25 12:01
Mainz Biomed Launches Feasibility Phase Of PancAlert Non-Invasive Blood Test For Early Pancreatic Cancer Detection Following 95% Sensitivity And 98% Specificity Results
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commencement of the next phase in its PancAlert
06-10 21:06
